ProPhase Labs, Inc. Logo

ProPhase Labs, Inc.

PRPH

(1.0)
Stock Price

0,70 USD

-33.99% ROA

-54.04% ROE

-1.67x PER

Market Cap.

44.262.120,00 USD

41.86% DER

0% Yield

-146.39% NPM

ProPhase Labs, Inc. Stock Analysis

ProPhase Labs, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ProPhase Labs, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (28%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.26x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-6.96%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-6.06%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-20) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

ProPhase Labs, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ProPhase Labs, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

ProPhase Labs, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ProPhase Labs, Inc. Revenue
Year Revenue Growth
1996 800.000
1997 70.200.000 98.86%
1998 36.400.000 -92.86%
1999 24.800.000 -46.77%
2000 19.364.186 -28.07%
2001 24.669.667 21.51%
2002 29.420.646 16.15%
2003 41.499.163 29.11%
2004 43.947.995 5.57%
2005 53.658.043 18.1%
2006 42.124.969 -27.38%
2007 39.475.381 -6.71%
2008 20.506.612 -92.5%
2009 19.816.000 -3.49%
2010 14.502.000 -36.64%
2011 17.453.000 16.91%
2012 22.406.000 22.11%
2013 25.032.000 10.49%
2014 22.070.000 -13.42%
2015 20.604.000 -7.12%
2016 21.014.000 1.95%
2017 9.867.000 -112.97%
2018 13.126.000 24.83%
2019 9.876.000 -32.91%
2020 14.514.000 31.96%
2021 79.042.000 81.64%
2022 122.647.000 35.55%
2023 33.460.000 -266.55%
2023 44.384.000 24.61%
2024 9.896.000 -348.5%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ProPhase Labs, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 1.185.750 100%
2001 1.331.639 10.96%
2002 2.663.291 50%
2003 3.365.698 20.87%
2004 3.232.569 -4.12%
2005 3.784.221 14.58%
2006 3.820.071 0.94%
2007 6.490.367 41.14%
2008 4.241.724 -53.01%
2009 1.308.000 -224.29%
2010 794.000 -64.74%
2011 1.088.000 27.02%
2012 1.301.000 16.37%
2013 824.000 -57.89%
2014 1.322.000 37.67%
2015 1.078.000 -22.63%
2016 575.000 -87.48%
2017 431.000 -33.41%
2018 398.000 -8.29%
2019 332.000 -19.88%
2020 633.000 47.55%
2021 520.000 -21.73%
2022 652.000 20.25%
2023 1.712.000 61.92%
2023 1.418.000 -20.73%
2024 556.000 -155.04%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ProPhase Labs, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 1.500.000
1997 13.500.000 88.89%
1998 15.800.000 14.56%
1999 23.900.000 33.89%
2000 18.228.880 -31.11%
2001 14.148.814 -28.84%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 -5.957.963.980 100%
2008 -5.944.129.841 -0.23%
2009 9.344.000 63714.4%
2010 6.054.000 -54.34%
2011 5.028.000 -20.41%
2012 6.127.000 17.94%
2013 5.893.000 -3.97%
2014 8.143.000 27.63%
2015 6.986.000 -16.56%
2016 5.063.000 -37.98%
2017 4.808.000 -5.3%
2018 4.910.000 2.08%
2019 4.480.000 -9.6%
2020 6.671.000 32.84%
2021 22.493.000 70.34%
2022 46.407.000 51.53%
2023 32.980.000 -40.71%
2023 34.502.000 4.41%
2024 28.848.000 -19.6%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ProPhase Labs, Inc. EBITDA
Year EBITDA Growth
1996 -700.000
1997 35.400.000 101.98%
1998 8.500.000 -316.47%
1999 -7.700.000 210.39%
2000 -5.570.112 -38.24%
2001 64.244 8770.24%
2002 -4.875.348 101.32%
2003 1.109.131 539.56%
2004 607.292 -82.64%
2005 4.383.537 86.15%
2006 -1.064.720 511.71%
2007 -2.239.907 52.47%
2008 -5.986.194 62.58%
2009 -3.944.000 -51.78%
2010 -3.231.000 -22.07%
2011 -2.383.000 -35.59%
2012 -3.146.000 24.25%
2013 661.000 575.95%
2014 -4.247.000 115.56%
2015 -3.584.000 -18.5%
2016 -2.229.000 -60.79%
2017 -3.609.000 38.24%
2018 -1.634.000 -120.87%
2019 -2.841.000 42.49%
2020 -3.465.000 18.01%
2021 14.006.000 124.74%
2022 28.809.000 51.38%
2023 -18.424.000 256.37%
2023 -14.915.000 -23.53%
2024 -24.392.000 38.85%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ProPhase Labs, Inc. Gross Profit
Year Gross Profit Growth
1996 800.000
1997 48.900.000 98.36%
1998 25.700.000 -90.27%
1999 17.100.000 -50.29%
2000 13.479.594 -26.86%
2001 15.054.456 10.46%
2002 12.211.810 -23.28%
2003 20.011.400 38.98%
2004 20.374.869 1.78%
2005 27.833.958 26.8%
2006 22.878.365 -21.66%
2007 22.648.319 -1.02%
2008 11.413.019 -98.44%
2009 11.569.000 1.35%
2010 8.830.000 -31.02%
2011 11.282.000 21.73%
2012 14.252.000 20.84%
2013 16.671.000 14.51%
2014 14.179.000 -17.58%
2015 12.178.000 -16.43%
2016 10.066.000 -20.98%
2017 1.948.000 -416.74%
2018 4.781.000 59.26%
2019 2.615.000 -82.83%
2020 4.606.000 43.23%
2021 32.814.000 85.96%
2022 70.654.000 53.56%
2023 9.308.000 -659.07%
2023 16.239.000 42.68%
2024 -1.904.000 952.89%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ProPhase Labs, Inc. Net Profit
Year Net Profit Growth
1996 -700.000
1997 21.000.000 103.33%
1998 6.800.000 -208.82%
1999 -4.200.000 261.9%
2000 -5.196.473 19.18%
2001 215.964 2506.18%
2002 -6.454.458 103.35%
2003 674.574 1056.82%
2004 452.862 -48.96%
2005 3.216.684 85.92%
2006 -1.748.345 283.98%
2007 -2.458.337 28.88%
2008 -5.534.286 55.58%
2009 -3.842.000 -44.05%
2010 -3.501.000 -9.74%
2011 -2.710.000 -29.19%
2012 -1.091.000 -148.4%
2013 405.000 369.38%
2014 -7.834.000 105.17%
2015 -3.600.000 -117.61%
2016 -2.868.000 -25.52%
2017 41.831.000 106.86%
2018 -1.740.000 2504.08%
2019 -3.013.000 42.25%
2020 -2.420.000 -24.5%
2021 6.273.000 138.58%
2022 18.463.000 66.02%
2023 -20.564.000 189.78%
2023 -16.782.000 -22.54%
2024 -24.612.000 31.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ProPhase Labs, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 2 100%
1998 1 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 -1 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 3 100%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 100%
2023 -1 200%
2023 -1 0%
2024 -1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ProPhase Labs, Inc. Free Cashflow
Year Free Cashflow Growth
1996 -1.100.000
1997 8.900.000 112.36%
1998 7.900.000 -12.66%
1999 300.000 -2533.33%
2000 -2.263.273 113.26%
2001 -1.485.233 -52.39%
2002 -37.225 -3889.88%
2003 -1.521.241 97.55%
2004 4.349.888 134.97%
2005 3.734.276 -16.49%
2006 259.464 -1339.23%
2007 -1.844.632 114.07%
2008 -3.257.356 43.37%
2009 237.000 1474.41%
2010 -4.702.000 105.04%
2011 -2.408.000 -95.27%
2012 -6.039.000 60.13%
2013 695.000 968.92%
2014 -3.528.000 119.7%
2015 -4.215.000 16.3%
2016 -1.123.000 -275.33%
2017 -3.046.000 63.13%
2018 -2.259.000 -34.84%
2019 -1.069.000 -111.32%
2020 -4.281.000 75.03%
2021 -17.850.000 76.02%
2022 24.632.000 172.47%
2023 -5.322.000 562.83%
2023 -14.503.000 63.3%
2024 -4.844.000 -199.4%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ProPhase Labs, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -1.100.000
1997 9.000.000 112.22%
1998 8.900.000 -1.12%
1999 1.300.000 -584.62%
2000 -1.869.796 169.53%
2001 -1.116.913 -67.41%
2002 543.636 305.45%
2003 -966.225 156.26%
2004 4.660.027 120.73%
2005 4.265.489 -9.25%
2006 956.943 -345.74%
2007 -1.311.598 172.96%
2008 -3.057.592 57.1%
2009 445.000 787.1%
2010 -3.549.000 112.54%
2011 -2.108.000 -68.36%
2012 -5.729.000 63.2%
2013 1.137.000 603.87%
2014 -3.216.000 135.35%
2015 -3.497.000 8.04%
2016 -472.000 -640.89%
2017 -2.838.000 83.37%
2018 -2.119.000 -33.93%
2019 -841.000 -151.96%
2020 -2.592.000 67.55%
2021 -13.619.000 80.97%
2022 28.551.000 147.7%
2023 -4.654.000 713.47%
2023 -11.348.000 58.99%
2024 -4.818.000 -135.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ProPhase Labs, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 0
1997 100.000 100%
1998 1.000.000 90%
1999 1.000.000 0%
2000 393.477 -154.14%
2001 368.320 -6.83%
2002 580.861 36.59%
2003 555.016 -4.66%
2004 310.139 -78.96%
2005 531.213 41.62%
2006 697.479 23.84%
2007 533.034 -30.85%
2008 199.764 -166.83%
2009 208.000 3.96%
2010 1.153.000 81.96%
2011 300.000 -284.33%
2012 310.000 3.23%
2013 442.000 29.86%
2014 312.000 -41.67%
2015 718.000 56.55%
2016 651.000 -10.29%
2017 208.000 -212.98%
2018 140.000 -48.57%
2019 228.000 38.6%
2020 1.689.000 86.5%
2021 4.231.000 60.08%
2022 3.919.000 -7.96%
2023 668.000 -486.68%
2023 3.155.000 78.83%
2024 26.000 -12034.62%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ProPhase Labs, Inc. Equity
Year Equity Growth
1996 1.200.000
1997 41.700.000 97.12%
1998 44.600.000 6.5%
1999 26.200.000 -70.23%
2000 21.208.018 -23.54%
2001 21.200.275 -0.04%
2002 18.422.817 -15.08%
2003 20.786.641 11.37%
2004 21.956.919 5.33%
2005 25.373.961 13.47%
2006 25.593.000 0.86%
2007 23.297.347 -9.85%
2008 17.773.878 -31.08%
2009 14.059.000 -26.42%
2010 13.460.000 -4.45%
2011 11.226.000 -19.9%
2012 11.451.000 1.96%
2013 12.596.000 9.09%
2014 10.716.000 -17.54%
2015 8.829.000 -21.37%
2016 5.962.000 -48.09%
2017 33.089.000 81.98%
2018 16.504.000 -100.49%
2019 11.231.000 -46.95%
2020 10.556.000 -6.39%
2021 58.628.000 81.99%
2022 63.631.000 7.86%
2023 49.383.000 -28.85%
2023 56.428.000 12.48%
2024 44.076.000 -28.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ProPhase Labs, Inc. Assets
Year Assets Growth
1996 1.400.000
1997 49.800.000 97.19%
1998 48.600.000 -2.47%
1999 33.300.000 -45.95%
2000 26.055.601 -27.8%
2001 24.755.795 -5.25%
2002 24.934.956 0.72%
2003 26.269.759 5.08%
2004 31.529.756 16.68%
2005 35.975.639 12.36%
2006 34.845.034 -3.24%
2007 33.313.718 -4.6%
2008 24.368.631 -36.71%
2009 19.817.000 -22.97%
2010 21.695.000 8.66%
2011 19.079.000 -13.71%
2012 16.661.000 -14.51%
2013 17.420.000 4.36%
2014 16.057.000 -8.49%
2015 14.829.000 -8.28%
2016 12.802.000 -15.83%
2017 34.161.000 62.52%
2018 20.737.000 -64.73%
2019 12.274.000 -68.95%
2020 31.405.000 60.92%
2021 89.295.000 64.83%
2022 87.648.000 -1.88%
2023 91.927.000 4.65%
2023 91.710.000 -0.24%
2024 93.678.000 2.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ProPhase Labs, Inc. Liabilities
Year Liabilities Growth
1996 200.000
1997 8.100.000 97.53%
1998 4.000.000 -102.5%
1999 7.100.000 43.66%
2000 4.847.583 -46.46%
2001 3.555.520 -36.34%
2002 6.512.139 45.4%
2003 5.483.118 -18.77%
2004 9.572.837 42.72%
2005 10.601.678 9.7%
2006 9.252.034 -14.59%
2007 10.016.371 7.63%
2008 6.594.753 -51.88%
2009 5.758.000 -14.53%
2010 8.235.000 30.08%
2011 7.853.000 -4.86%
2012 5.210.000 -50.73%
2013 4.824.000 -8%
2014 5.341.000 9.68%
2015 6.000.000 10.98%
2016 6.840.000 12.28%
2017 1.072.000 -538.06%
2018 4.233.000 74.68%
2019 1.043.000 -305.85%
2020 20.849.000 95%
2021 30.667.000 32.01%
2022 24.017.000 -27.69%
2023 42.544.000 43.55%
2023 35.282.000 -20.58%
2024 49.602.000 28.87%

ProPhase Labs, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.95
Net Income per Share
-1.39
Price to Earning Ratio
-1.67x
Price To Sales Ratio
2.46x
POCF Ratio
-2.96
PFCF Ratio
-2.49
Price to Book Ratio
0.99
EV to Sales
3.82
EV Over EBITDA
-2.58
EV to Operating CashFlow
-4.64
EV to FreeCashFlow
-3.87
Earnings Yield
-0.6
FreeCashFlow Yield
-0.4
Market Cap
0,04 Bil.
Enterprise Value
0,07 Bil.
Graham Number
8.55
Graham NetNet
-1.09

Income Statement Metrics

Net Income per Share
-1.39
Income Quality
0.56
ROE
-0.54
Return On Assets
-0.28
Return On Capital Employed
-0.52
Net Income per EBT
0.74
EBT Per Ebit
1.05
Ebit per Revenue
-1.89
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
1.73
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0.22
Gross Profit Margin
-0.09
Operating Profit Margin
-1.89
Pretax Profit Margin
-1.99
Net Profit Margin
-1.46

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.78
Free CashFlow per Share
-0.94
Capex to Operating CashFlow
-0.2
Capex to Revenue
0.16
Capex to Depreciation
0.4
Return on Invested Capital
-0.4
Return on Tangible Assets
-0.34
Days Sales Outstanding
668.93
Days Payables Outstanding
253.66
Days of Inventory on Hand
71.98
Receivables Turnover
0.55
Payables Turnover
1.44
Inventory Turnover
5.07
Capex per Share
0.16

Balance Sheet

Cash per Share
0,13
Book Value per Share
2,33
Tangible Book Value per Share
1.47
Shareholders Equity per Share
2.33
Interest Debt per Share
1.08
Debt to Equity
0.42
Debt to Assets
0.2
Net Debt to EBITDA
-0.92
Current Ratio
1.58
Tangible Asset Value
0,03 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
52173000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.17
Average Receivables
0,03 Bil.
Average Payables
0,01 Bil.
Average Inventory
3812500
Debt to Market Cap
0.42

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ProPhase Labs, Inc. Dividends
Year Dividends Growth
2018 1
2019 1 0%
2021 0 0%
2022 1 0%

ProPhase Labs, Inc. Profile

About ProPhase Labs, Inc.

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

CEO
Mr. Ted William Karkus
Employee
113
Address
711 Stewart Avenue
Garden City, 11530

ProPhase Labs, Inc. Executives & BODs

ProPhase Labs, Inc. Executives & BODs
# Name Age
1 Mr. Jed A. Latkin
Chief Operating Officer & Head of Finance Department
70
2 Mr. Sergio Miralles
Executive Vice President & Chief Information Officer
70
3 Mr. Kamal Obbad
Senior Vice President and Director of Sales & Marketing - Nebula Genomics
70
4 Mr. Lance Bisesar
Corporate Controller
70
5 Mr. Jason Karkus
President of Nebula Genomics
70
6 Mr. Ted William Karkus
Chairman & Chief Executive Officer
70

ProPhase Labs, Inc. Competitors